



VALEO PHARMA™

**PRESS RELEASE  
FOR IMMEDIATE DISTRIBUTION**

## **VALEO PHARMA TO REPORT FOURTH QUARTER AND 2020 YEAR-END RESULTS AND HOLD INVESTORS CONFERENCE CALL / WEBCAST**

MONTREAL, QUEBEC , February 19, 2021 – [Valeo Pharma Inc.](#) (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian specialty pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2020 on Wednesday February 24, 2021 after market close.

Valeo will host a conference call to discuss those results and highlights on Thursday February 25, 2021 at 8.30am (EST). The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (1498873).

A live audio webcast of the conference call will be available via:  
[https://produceredition.webcasts.com/starthere.jsp?ei=1433860&tp\\_key=71fe5003d2](https://produceredition.webcasts.com/starthere.jsp?ei=1433860&tp_key=71fe5003d2)

### **About Valeo Pharma**

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit [www.valeopharma.com](http://www.valeopharma.com) and follow us on [LinkedIn](#) and [Twitter](#).

### **Forward Looking Statements**

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.



VALEO PHARMA™

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For more information:

Steve Saviuk  
President and CEO  
514-693-8830  
[saviuk@valeopharma.com](mailto:saviuk@valeopharma.com)

or

Luc Mainville  
Senior Vice-President and Chief Financial Officer  
514-693-8854  
[mainville@valeopharma.com](mailto:mainville@valeopharma.com)

or

Frederic Dumais  
Director, Communications and Investor Relations  
514-782-8803  
[dumais@valeopharma.com](mailto:dumais@valeopharma.com)